RANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.

Can quality of life research learn from restaurant reviews?

How to design a trial to test the efficacy of Lutetium-PSMA products in metastatic castration-resistant prostate cancer?

SPLASH - a problematic trial design for an active Lutetium-PSMA product in metastatic castrate-resistant prostate cancer

After 23 years, imatinib remains the best front-line therapy in CML. Why use accelerated approval in a setting where patients have a life expectancy comparable to the general population?

Special post-ESMO 2024 edition !

Artificial Intelligence in Medicine - My Keynote

Debate over pembrolizumab dosing gives rise to a national guidance on de-escalation strategies and off-label use

Challenges with Reproducibility

Lu-PSMA and the need to 'educate' medical professionals about its use.

Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances.

The scattergun approach in research - a deep dive into CDK4/6 inhibitors tested in the neoadjuvant setting.